Short-term Effect of Infliximab Is Reflected in the Clot Lysis Profile of Patients with Inflammatory Bowel Disease

Abstract

This is the first prospective study demonstrating that the clot lysis profile differs between patients with IBD and healthy individuals. On infliximab induction treatment, this clot lysis profile normalizes in responders suggesting that infliximab treatment is advisable for patients with IBD with an activated hemostatic profile.

Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study

“…14,27,28 Our data support the notion that more aggressive control of inflammation in IBD by means of TNF-α inhibition may lead to reductions in coagulation and fibrinolysis, which ultimately could reduce the risk of VTE. The observed protective association between TNF-α inhibitor use and VTE was strongest for young patients, which suggests that when IBD is the predominant risk factor for VTE, aggressive inflammation control with TNF-α inhibitors may lead to clinically significant VTE risk reduction.…”

“…13,14 However, it is not known whether use of TNF-α inhibitors reduces major VTE events in patients with IBD to a greater extent than use of other (nonbiologic) immunomodulatory treatments.…”

Identification of an inflammatory bowel disease patient with a deep vein thrombosis and an altered clot lysis profile

“…We have recently reported that patients with IBD who respond to infliximab treatment show a normalization of their initially altered clot lysis profile. The thromboembolic event prevalence in the IBD population included in this study was 5%, but only one patient developed thromboembolic event during the study [3]. We here report the case of this latter patient, a 31-year-old female patient with IBD.…”

“…In the follow-up of the institutional review board-approved B322201213950/S53684 prospective study described in Bollen et al [3], a 31-year-old woman (diagnosed with IBD 9 years ago) developed a deep vein thrombosis. October 2010, the patient received a first infusion of infliximab in combination with azathioprine for uncontrolled disease, with a second infusion at week 2 and a third infusion at week 6 (November 2010).…”

“…They have shown that hypofibrinolysis identified by a clot lysis assay is a risk factor for the development of a first deep vein thrombosis. Recently, we have demonstrated that clot lysis profiles of patients with IBD and healthy individuals differ [3].…”